Reducing The Health Risks Of Obesity Without Serious Side Effects
The drug rimonabant was developed as a treatment for obesity and its myriad of serious health consequences (for example, type 2 diabetes). Despite having its desired effects on weight, which it decreased, and on levels of glucose and fats in the blood, rimonabant was never approved for use in the US because of serious neurological side effects including depression and anxiety. Now, a team of …
Read more on redOrbit
US FDA approves Tribenzor, a new three-in-one combo product for high blood pressure treatment
Daiichi Sankyo, Inc. announced that the US Food and Drug Administration (FDA) approved Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide), a new three-in-one combination product taken once-daily for the treatment of hypertension in patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel …
Read more on PharmaBiz
Predicting drug responsiveness in cancer patients
Drugs that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment. Now, a team of researchers has identified a way to help predict which patients will respond to such drugs.
Read more on Science Daily
Medicare Cut in Dialysis Fees May Slash Amgen Sales of Anemia Drug Epogen
Use of Amgen Inc.’s Epogen, the world’s top-selling anemia drug, is likely to fall under rules imposed on kidney dialysis centers by Medicare , the U.S. health program for the elderly and disabled.
Read more on Bloomberg
Recent Comments